



US government (USG) investment in global health R&D has delivered

**\$94.1 million**  
to Florida research institutions\*

**1,500+** new jobs  
for Florida†

Florida's top global health R&D institutions by USG funding\*

ORGANIZATION	FUNDING
University of Miami	\$22.5 million
University of South Florida	\$15.6 million
University of Central Florida	\$15.4 million
University of Florida	\$12.4 million
Florida State University	\$9.7 million
Vaccine and Gene Therapy Institute of Florida	\$5.2 million
Torrey Pines Institute for Molecular Studies	\$4.0 million

Neglected diseases in Florida‡

HIV diagnoses	43,431
Tuberculosis cases	6,531
Zika cases	1,216
Dengue cases	779
Malaria cases	604

Florida industry in global health R&D


**Bristol-Myers Squibb:** Tampa  
**Celgene:** Destin  
**Cipla:** Sunrise  
**Novartis:** Miami, Plantation  
**Sanofi:** Orlando

Global health R&D at work in the Sunshine State



University of Florida scientists are studying how Florida mosquito species spread chikungunya virus. The virus, which occurs mostly in Africa, Asia, and India, arrived in the Caribbean several years ago; since then, more than 3,800 cases have been diagnosed in Florida. The virus causes fever, headaches, muscle and joint pain, and, in some cases, chronic rheumatoid arthritis. The study will help scientists model chikungunya transmission to better control outbreaks.

Florida's top areas of global health R&D by USG funding\*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES\*

**89¢** of every dollar  
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

**200K** new US jobs

**\$33 BILLION** in US economic growth.

\*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See [www.ghtcoalition.org](http://www.ghtcoalition.org) for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, Zika virus disease cases 2015-2017, Dengue virus infection cases 2010-2016, Malaria cases 2008-2014.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.